Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

Bayer breaks losing streak with Roundup trial victory!

Breaking: Bayer's courtroom comeback! After a losing streak, the latest Roundup cancer trial ends in victory, putting an end to their legal woes. #Bayer #R...

Top News

Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio

Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a biopharmaceutical company that has developed a new antipsychotic, in a $14 billion deal

The Independent UK

Macron's new health minister implicated in luxury gifts scandal

France's new health minister, Agnès Firmin Le Bodo, on Friday confirmed she was among several pharmacists under investigation for allegedly accepting gifts from one of the country's top laboratories. Firmin Le Bodo was appointed after her predecessor resigned in protest at the government's contentious new immigration law.

Radio France Internationale

From analysis to the latest developments in health,
read the most diverse news in one place.

In 2023, opioid settlement funds flowed to states. Here's how it's going

Some $1.5 billion flowed to local government coffers this year, sparking debates about transparency and how to spend the money. Here are 5 takeaways from a year's worth of reporting on the issue.

WEKU

3 Pharma Powerhouses to Watch Closely

The pharmaceutical industry is expected to thrive amid robust demand and technological advancements. Therefore, it could be wise to keep an eye on top pharma stocks, Roche Holding (RHHBY), Novartis (NVS) and AbbVie (ABBV). Continue reading.

StockNews.com

Bold Brews Beat Weight-Loss Drugs: Nestle CEO's Confident Declaration

Weight-loss drugs no match for Nestle's coffee empire, claims CEO. Discover how Nestle plans to keep their caffeine-filled kingdom thriving!

Top News

Analyzing 3 Pharma Stocks for Year-End Gains?

The pharma industry is well-positioned for expansion owing to growing healthcare spending and the adoption of cutting-edge technologies to develop new drugs. Amid this backdrop, let’s analyze the investment prospects of fundamentally strong pharma stocks Eli Lilly (LLY), Teva Pharmaceutical (TEVA), and Johnson & Johnson (JNJ) for year-end gains. Read…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Analyzing Buy or Hold Options for 3 Medical Stocks

The medical industry is thriving due to rising demand for healthcare products and services, fueling significant returns. Given the solid long-term prospects of the industry, let’s analyze fundamentally sound medical stocks McKesson (MCK), Zimmer Biomet (ZBH) and Fresenius SE (FSNUY).

StockNews.com

Pfizer Sues Poland And Hungary Over Covid Debts

Pharmaceutical firms Pfizer and BioNTech are suing the governments of Poland and Hungary alleging they failed to pay for vaccines ordered during the Covid pandemic, lawyers said Tuesday.

International Business Times

The good news for women: a drug to limit hot flushes. The bad: it could cost you £430 a month

Veoza reduces the severity of this common menopausal symptom. But at £430 a month, only the wealthy will gain just now, says Guardian columnist Devi Sridhar

The Guardian - UK

Are These 3 Pharma Stocks Smart Buys for Bullish Investors?

The pharmaceutical industry's outlook looks promising, given robust healthcare spending worldwide and the rapid adoption of advanced digital technologies. Amid this, let’s find out if pharma stocks AbbVie (ABBV), Collegium Pharmaceutical (COLL), and Merck (MRK) are ideal buys now. Read on to know more….

StockNews.com

How the Michelle Mone scandal unfolded: £200m of PPE contracts, denials and a government lawsuit

Conservative peer made multiple denials of any association between her and PPE Medpro

The Guardian - UK

Supreme Court to Review Nationwide Restrictions on Abortion Pill

US Supreme Court to decide on restricting abortion drug Mifepristone. Attorney General Bob Ferguson discusses potential ramifications and possible tactics.

Top News

Stakeholders express dismay as Centre readies to regulate medical devices alongside drugs

Concerned groups express dismay over proposed New Drugs, Cosmetics and Medical Device Bill, 2023, citing inadequate addressing of key issues and lack of external input.

The Hindu

Get all your
news in one place.

100's of premium titles.
One news app.

Top News

FDA Spots Control Irregularities in Moderna's US Plant

Dive into the intriguing saga of unanticipated control failures at Moderna's magnate production plant, a juicy scoop exclusively unraveled by the meticulou...

The Independent UK

Older Americans to pay less for some drug treatments as drugmakers penalized for big price jumps

Hundreds of thousands of older Americans could pay less for outpatient drug treatments beginning early next year

The Independent UK

Vivek Ramaswamy spins conspiracy theories at bad-tempered CNN town hall

Republican presidential candidate sparred with host Abby Phillip at Iowa event

International Business Times

Pfizer Shares Tumble On Disappointing 2024 Profit Outlook

Pfizer issued a disappointing 2024 forecast Wednesday, denting shares as the company navigates a profound plunge in sales tied to the Covid-19 pandemic.

Get all your
news in one place.

100's of premium titles.
One news app.

Top News

Supreme Court to Consider Restrictions on Abortion Drug Mifepristone

The Supreme Court is reconsidering the accessibility of popular abortion drug, Mifepristone, a high-stakes case with potential electoral repercussions.

The Hindu

Committee recommends curbs on freebies doled out by pharma companies

Committee recommends revising UCPMP to prohibit CMEs in foreign locations, disclose price of gifts to doctors, and make money received by doctors from pharma cos for research taxable.

Top News

FDA Seeks Power for Eyedrops Recalls Amid Foreign Inspections Woes

U.S. health officials grapple with inadequate inspection of overseas eyedrop factories, leading to recalls of potentially dangerous products.

The Independent UK

Safer eyedrops will require new FDA powers and resources, experts say

Repeated recalls of eyedrops are drawing new attention to the limited powers U.S. regulators have to oversee medical products made overseas

The Guardian - UK

AstraZeneca buys US vaccine company in $1.1bn deal

Britain’s biggest drugmaker acquires Seattle-based firm Icosavax, expanding vaccine and immune therapy business

StockNews.com

Citius Pharmaceuticals (CTXR) Earnings Watch: Pharma Stock Signals for Investors

Citius Pharmaceuticals (CTXR) has been making significant progress in its pipeline, garnering investors' attention. However, considering that CTXR is an unprofitable and pre-revenue business, is it worth investing now as the company prepares to report quarterly results? Keep reading.

StockNews.com

3 Pharma Powerhouses to Boost Your Year-End Investments

Backed by an ever-growing need for chronic disease treatments, rapid investments in research and development, and widespread integration of technology, the pharmaceutical sector is anticipated to flourish. Thus, as we approach the end of 2023, three solid pharma stocks, GoodRx Holdings (GDRX), CytomX Therapeutics (CTMX), and Neurocrine Biosciences (NBIX), could…

1 … 40 41 42 43

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

National Crime Agency

315 stories

Merck

302 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.